New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs Kisspeptin-10

Retatrutide vs Kisspeptin-10

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
Half-Life
~10–12 days
~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
Admin Route
SubQ
SubQ, IV
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
50–500 mcg
Frequency
Once weekly
Once daily to every other day
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Potently stimulates LH and testosterone
  • Enhances sexual arousal and libido
  • Activates HPG axis — upstream of GnRH
  • May improve fertility in hypogonadotropic hypogonadism
  • Increases brain activation in sexual attraction circuits
  • May restore LH pulsatility in suppressed HPG axis
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Injection site reactions
  • Temporary nausea
  • Flushing
  • Elevated LH/testosterone (intended effect)
  • +1 more
Stacks With